A Phase I, Open Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Irinotecan and Cetuximab for the Relapsed or Refractory Metastatic Colorectal Cancer.

Trial Profile

A Phase I, Open Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Irinotecan and Cetuximab for the Relapsed or Refractory Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Pazopanib (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Mar 2012 Actual end date changed from Mar 2010 to May 2010 as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top